Insider Selling: Danaher (NYSE:DHR) Director Sells 3,298 Shares of Stock

Danaher Corporation (NYSE:DHR) Director Teri List sold 3,298 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Teri List also recently made the following trade(s):

• On Friday, August 22nd, Teri List sold 2,778 shares of Danaher stock. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68.

Danaher Trading Down 1.3%

NYSE DHR traded down $2.93 during trading on Wednesday, reaching $222.58. 4,483,261 shares of the stock traded hands, compared to its average volume of 4,202,454. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The firm has a market cap of $157.22 billion, a price-to-earnings ratio of 45.89, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The stock’s 50-day moving average price is $206.70 and its 200 day moving average price is $201.47.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the firm posted $1.71 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Institutional Trading of Danaher

Several institutional investors have recently added to or reduced their stakes in DHR. JPL Wealth Management LLC acquired a new position in shares of Danaher in the third quarter valued at about $25,000. WFA of San Diego LLC bought a new position in shares of Danaher during the second quarter worth approximately $26,000. Howard Hughes Medical Institute acquired a new stake in shares of Danaher in the second quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Danaher in the third quarter valued at approximately $27,000. Finally, TruNorth Capital Management LLC acquired a new stake in Danaher during the third quarter worth approximately $28,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on DHR shares. Rothschild Redb cut Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Evercore ISI upped their target price on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Finally, Redburn Partners set a $220.00 price target on shares of Danaher in a research note on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.